- (Z)-LFM-A13
-
- $30.00
-
2026-05-11
- CAS:244240-24-2
- Purity: 99.90%
- Supply Ability: 10g
- LFM-A13
-
- $1.00
-
2019-07-06
- CAS:244240-24-2
- Min. Order: 1KG
- Purity: 98-100%
- Supply Ability: 1000kg
|
| | LFM-A13 Basic information |
| Product Name: | LFM-A13 | | Synonyms: | α-cyano-β-hydroxy-β-methyl-n-(2,5-dibromophenyl)propenamide;(Z)-2-cyano-N-(2,5-dibroMophenyl)-3-hydroxybut-2-enaMide(LFM-A13);(Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide;(2Z)-2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide;a-Cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl)propenamide;2-cyano-N-(2,5-dibromophenyl)
-3-oxobutanamide;LFM-A13(Z);2-Butenamide,2-cyano-N-(2,5-dibromophenyl)-3-hydroxy-, (2Z)- | | CAS: | 244240-24-2 | | MF: | C11H8Br2N2O2 | | MW: | 360 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 244240-24-2.mol |  |
| | LFM-A13 Chemical Properties |
| Melting point | 150-151 °C | | Boiling point | 487.9±45.0 °C(Predicted) | | density | 1.909±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | DMSO: 15 mg/mL | | form | powder | | pka | 5.20±0.50(Predicted) | | color | white | | Stability: | Stable for 2 years from date of purchase as supplied. PROTECT FROM MOISTURE. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. | | InChI | InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6- | | InChIKey | UVSVTDVJQAJIFG-VURMDHGXSA-N | | SMILES | C(NC1=CC(Br)=CC=C1Br)(=O)/C(/C#N)=C(\O)/C |
| Hazard Codes | Xn | | Risk Statements | 20/21/22 | | Safety Statements | 36/37 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Dermal
Acute Tox. 4 Inhalation
Acute Tox. 4 Oral |
| | LFM-A13 Usage And Synthesis |
| Description | LFM-A13 (244240-24-2) is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC50‘s = 2.5 μM (recombinant BTK) and 17.2 μM (human BTK).1,2 It has also been shown to inhibit Polo-like kinase (PLK) – IC50 = 61 μM for human PLK3.3 LFM-A13 displayed no activity (concentrations up to 278 μM) at JAK1, JAK3, HCK, EGFRK and IRK2 or CDK1-3, CHK1, IKK, MAPK1, SAPK2a and ten other tyrosine kinases.3 | | Uses | LFM-A13 is a potent inhibitor of Polo-like kinase (PLK), used for anti-breast cancer activity. Also a specific Bruton’s tyrosine kinase inhibitor. | | in vitro | lfm-a13 inhibited recombinant btk expressed in a baculovirus expression vector system. besides its remarkable potency in btk kinase assays, lfm-a13 was also found to be a highly specific inhibitor of btk. even at very high concentrations, lfm-a13 did not affect the activity of other protein tyrosine kinases [1]. | | in vivo | lfm-a13 exhibited a favorable pharmacokinetic behavior which was not adversely affected by the standard chemotherapy drugs and significantly improved the chemotherapy response and survival outcome of bcl-1 leukemia cells challenged mice. while only 14% of mice treated with the standard triple-drug combination treatment became long-term survivors, 41% of mice treated with this combination plus lfm-a13 survived long-term [2]. | | IC 50 | 17.2 μm | | References | [1] Bruton’s tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex
[2] Rational design and synthesis of a novel-anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide]
[3] FATIH M. UCKUN. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK)[J]. Bioorganic & Medicinal Chemistry, 2007, 15 2: Pages 800-814. DOI:10.1016/j.bmc.2006.10.050 |
| | LFM-A13 Preparation Products And Raw materials |
|